ConsumerLab on hoodia
This article was originally published in The Tan Sheet
Executive SummaryEvidence supporting the efficacy and safety of hoodia gordonii as a weight loss ingredient "remains anecdotal and preliminary," ConsumerLab.com concludes in an Oct. 20 review article, citing the lack of a "scientific standard for assessing the quality of the ingredient." According to the group, "no one knows for certain how much hoodia should be taken" since no clinical trials have been published to determine an optimal dose that is safe and effective. "The market is ahead of the science," ConsumerLab President Tod Cooperman noted. The report warns that it is "uncertain which products on the market provide the authentic ingredient and whether they recommend an appropriate dose"...
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.